These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28116088)

  • 21. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
    Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
    J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
    He J; Shen D; O'Donnell MA; Chang HR
    Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
    Barratt-Boyes SM; Vlad A; Finn OJ
    Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
    Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
    J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice.
    Fang F; Ma J; Ni W; Wang F; Sun X; Li Y; Li Q; Xie F; Wang J; Zhai R; Liu Z; Gao S; Tai G
    Mol Med Rep; 2014 Aug; 10(2):1056-64. PubMed ID: 24912810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
    Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
    Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
    Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
    Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
    Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
    J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model.
    Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Tezuka N; Sawai S; Inoue S; Fujino S; Maeda T; Itoh Y; Ogasawara K; Sato H; Ohkubo I; Kudo T
    Cancer Gene Ther; 2002 Apr; 9(4):330-7. PubMed ID: 11960283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
    Shi FF; Gunn GR; Snyder LA; Goletz TJ
    Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
    Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
    Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization.
    Lees CJ; Apostolopoulos V; McKenzie IF
    J Interferon Cytokine Res; 1999 Dec; 19(12):1373-9. PubMed ID: 10638706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
    Mukherjee P; Pathangey LB; Bradley JB; Tinder TL; Basu GD; Akporiaye ET; Gendler SJ
    Vaccine; 2007 Feb; 25(9):1607-18. PubMed ID: 17166639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
    Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth.
    Yuan S; Shi C; Lv Y; Wang T; Wang H; Han W
    Cancer Biother Radiopharm; 2009 Oct; 24(5):607-13. PubMed ID: 19877891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.